Stocks and Investing Stocks and Investing
Wed, March 9, 2022
Tue, March 8, 2022
Mon, March 7, 2022
Sun, March 6, 2022
Fri, March 4, 2022

Bradley Canino Maintained (BPMC) at Strong Buy with Increased Target to $105 on, Mar 4th, 2022


Published on 2024-10-27 19:57:37 - WOPRAI, Bradley Canino
  Print publication without navigation


Bradley Canino of Stifel, Maintained "Blueprint Medicines Corporation" (BPMC) at Strong Buy with Increased Target from $100 to $105 on, Mar 4th, 2022.

Bradley has made no other calls on BPMC in the last 4 months.



There are 6 other peers that have a rating on BPMC. Out of the 6 peers that are also analyzing BPMC, 3 agree with Bradley's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • David Lebowitz of "Citigroup" Initiated at Hold on, Tuesday, March 1st, 2022
  • Andrew Berens of "SVB Leerink" Downgraded from Buy to Hold and Decreased Target to $82 on, Thursday, February 17th, 2022
  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $92 on, Tuesday, February 1st, 2022


These are the ratings of the 3 analyists that currently disagree with Bradley


  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $100 on, Thursday, February 17th, 2022
  • Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Increased Target to $122 on, Monday, January 3rd, 2022
  • Dane Leone of "Raymond James" Maintained at Strong Buy with Increased Target to $133 on, Wednesday, November 10th, 2021